Breast Cancer

Fam-trastuzumab deruxtecan-nxki conferred a statistically significant and clinically meaningful PFS benefit among patients with unresectable and/or metastatic HER2-positive breast cancer, according to data from the agent’s manufacturer.

Abemaciclib resulted in an approximately twofold higher venous thromboembolism rate in a real-world setting compared with clinical trials among patients with metastatic breast cancer, according to study results published in Cancer.

Researchers at Johns Hopkins Sidney Kimmel Cancer Center have developed an automated liquid biopsy test that can detect cancer DNA in the blood of patients with metastatic breast cancer within 5 hours.

The FDA granted fast track designation to several oncology and hematology therapies.

The FDA approved fam-trastuzumab deruxtecan-nxki for treatment of certain patients with unresectable or metastatic HER2-low breast cancer.

CHICAGO — Living in a formerly redlined census tract at the time of diagnosis was linked with worse all-cause and breast cancer mortality, according to a poster presented at ASCO Annual Meeting.

CHICAGO — Healio spoke with Clement A. Adebamowo, MD, ScD, about his poster presentation at ASCO Annual Meeting regarding breast cancer subtype testing in Nigeria.

In this episode, menopausal hormone therapy is not associated with breast cancer recurrence and mortality; pandemic-related screening declines may result in ‘increased avoidable cancer deaths’; data on pertuzumab regimen in early breast cancer; and more.

Researchers led by a Yale University team have developed a new measure for neoadjuvant chemotherapy efficacy for use in preoperative breast cancer trials.

Results of a phase 1/phase 2 study showed similar treatment outcomes among Black and non-Black women who received durvalumab plus chemotherapy prior to surgery for triple-negative breast cancer.